The final hearing on drug-maker Novartis’ petition challenging the rejection of its patent application for cancer drug Glivec has been adjourned to late next month.
“Following the unavailability of the Senior Counsel representing Novartis, a joint request for adjournment was made to the Bench. The request was accepted and the case is now listed for August 22,” a Novartis statement said.
The Swiss drug-major Novartis AG is challenging the rejection of its patent application (in 2006) for the beta-crystalline form of imatinib mesylate (sold under the brandname Glivec).
The high-profile case will set a benchmark as it further clarifies the implementation of the amended Indian Patents Acts – particularly on issues regarding the interpretation and assessment of efficacy of the medicine seeking a product patent.